Factor B vs C5 inhibitors in PNH: EVH control

Why C5 inhibitors leave extravascular hemolysis uncontrolled

Eculizumab and ravulizumab block the terminal complement cascade at C5, preventing membrane attack complex (MAC) formation and eliminating intravascular hemolysis (IVH) — but they do not prevent upstream C3 activation. Because PNH erythrocytes lack CD55 (decay-accelerating factor), which normally regulates C3 convertase, C3 fragments — C3b, iC3b, and C3dg — continuously deposit on cell surfaces even when C5 is fully blocked. These C3-opsonized erythrocytes are then recognised by complement receptor 3 (CR3) on splenic and hepatic macrophages and cleared by phagocytosis, a process entirely invisible to terminal pathway inhibitors.

The clinical consequence of this gap is significant. Pivotal trials of eculizumab (TRIUMPH, SHEPHERD) and ravulizumab demonstrated excellent LDH normalisation — exceeding 90% of patients — and an approximately 85% reduction in thrombotic events. Yet mean hemoglobin in treated patients stabilises at only 9–11 g/dL, well below the normal range of 12–16 g/dL. Between 18% and 31% of patients remain transfusion-dependent despite adequate IVH control, and persistent reticulocytosis confirms that hemolysis continues through a non-MAC mechanism. As documented in studies cited by The New England Journal of Medicine and reviewed by the European Medicines Agency, C3dg deposition on PNH erythrocytes is detectable in all eculizumab- and ravulizumab-treated patients, confirming that C3-mediated erythrophagocytosis is the dominant residual hemolytic mechanism.

Persistent C3 opsonisation also explains why PNH clone size can paradoxically increase on C5 inhibitors: complement-sensitive PNH cells survive IVH but accumulate C3 tags, enlarging the pool of erythrocytes vulnerable to extravascular clearance. For patients with high clone burden, this dynamic amplifies the EVH problem over time, creating a clinical scenario where better IVH control coincides with worsening anemia from the extravascular route.

The mechanistic case for proximal alternative pathway inhibition

Factor B inhibitors (iptacopan) and Factor D inhibitors (danicopan) target the assembly of the alternative pathway C3 convertase (C3bBb), intercepting complement activation before C3 cleavage occurs. Because the alternative pathway is responsible for 80–90% of complement amplification in PNH, blocking it upstream prevents both the C3 opsonisation that drives EVH and the downstream C5 convertase formation that drives IVH — achieving dual hemolysis control from a single molecular target.

The biological specificity of Factor B/D inhibitors is a critical differentiator. Unlike pan-complement inhibitors that block C3 directly — such as pegcetacoplan — Factor B and Factor D inhibitors selectively target the alternative pathway, leaving the classical and lectin pathways intact for pathogen defence. Factor B is the serine protease that, once bound to C3b, forms the active C3 convertase (C3bBb); Factor D then cleaves Factor B to activate this complex. Iptacopan occupies the Factor B active site, preventing C3bBb assembly. Danicopan inhibits Factor D, the rate-limiting enzyme of the AP, achieving the same upstream blockade through a different molecular mechanism.

"C5 inhibitors do not interrupt the alternative pathway amplification loop — allowing continuous C3 opsonisation of PNH erythrocytes. Factor B/D inhibitors break this amplification cycle at its source, preventing C3b accumulation entirely."

This mechanistic distinction is reinforced by the biology of the amplification loop itself. Each C3b molecule deposited on an erythrocyte surface can recruit additional Factor B and Factor D to assemble new C3 convertases, exponentially amplifying C3b deposition. Because C5 inhibitors do not interrupt this loop, C3 opsonisation escalates with every complement activation event. Factor B/D inhibitors prevent the initial C3b deposition that seeds this loop, making them inherently more effective at controlling cumulative C3-mediated damage. According to the FDA's regulatory review of iptacopan, near-complete suppression of C3 fragment deposition — Fragment Bb reduced by more than 95% — was confirmed as the pharmacodynamic mechanism underlying the drug's clinical superiority.

Phase 3 trial evidence: iptacopan and danicopan vs C5 inhibitors

The APPLY-PNH and APPOINT-PNH trials for iptacopan and the ALPHA trial for danicopan provide the pivotal clinical evidence that proximal AP inhibition achieves hemoglobin normalisation rates and transfusion independence rates that C5 inhibitors cannot match — particularly in patients with residual anemia driven by EVH.

APPLY-PNH: Iptacopan monotherapy vs continued C5 inhibition

The APPLY-PNH Phase 3 trial enrolled PNH patients with residual anemia (hemoglobin ≥10 g/dL) despite ongoing eculizumab or ravulizumab therapy — precisely the population in whom EVH is the dominant hemolytic mechanism. Patients were randomised to iptacopan 200 mg twice daily or continued C5 inhibitor. At the 24-week primary endpoint, 82% of iptacopan patients achieved a hemoglobin increase of ≥2 g/dL, compared with 2% on C5 inhibitors (p<0.001). Critically, 69% of iptacopan patients reached hemoglobin ≥12 g/dL — the lower bound of the normal range — versus 0% on C5 inhibitors. Mean hemoglobin increased by +3.84 g/dL with iptacopan.

APPOINT-PNH: Iptacopan as first-line therapy

The APPOINT-PNH Phase 3 trial extended the evidence base to treatment-naïve PNH patients. Iptacopan monotherapy achieved hemoglobin normalisation and transfusion avoidance in complement-inhibitor-naïve patients, establishing the drug's efficacy as a potential first-line therapy. Long-term follow-up data spanning 4–5 years confirm sustained hemoglobin stabilisation and transfusion independence, with no increase in breakthrough hemolysis events compared to C5 inhibitors.

ALPHA Trial: Danicopan add-on for EVH on C5 inhibitors

Danicopan takes a different strategic position: rather than replacing C5 inhibitor therapy, it augments it. The ALPHA Phase 3 trial enrolled PNH patients with clinically evident EVH already on eculizumab or ravulizumab. Adding danicopan 150 mg three times daily produced significant hemoglobin increases, reduced transfusion requirements, and suppressed C3 deposition and reticulocytosis markers. The FDA and EMA approved danicopan specifically for this EVH indication — a dual-target approach that provides proximal AP inhibition while maintaining terminal pathway blockade with the existing C5 inhibitor.

Why proximal inhibition outperforms terminal blockade: three mechanistic reasons

Three distinct biological mechanisms explain why Factor B/D inhibitors achieve superior hemolysis control compared with C5 inhibitors in PNH — and why this advantage is structural rather than incidental.

1. Amplification loop suppression

The alternative pathway functions as a self-amplifying feedback cycle: each C3b molecule deposited on a cell surface recruits Factor B and Factor D to form additional C3 convertases, exponentially increasing C3b deposition. C5 inhibitors do not interrupt this loop — they allow C3b accumulation to continue unchecked while blocking only the terminal output. Factor B/D inhibitors break the amplification cycle at its source, preventing C3b accumulation from initiating. This is particularly important during strong complement triggers such as infections, surgery, or inflammation, when high-density C3b deposition can overwhelm terminal pathway blockade and cause pharmacodynamic breakthrough hemolysis.

2. Erythrocyte lifespan extension

C5 inhibitors extend PNH erythrocyte lifespan from days to weeks by preventing MAC-mediated lysis, but C3-opsonised cells still undergo premature removal via the reticuloendothelial system. Proximal inhibitors allow PNH erythrocytes to achieve near-normal lifespan by preventing C3 tagging entirely. This is evidenced by the increase in PNH clone size — up to 80–90% of circulating red blood cells — observed in iptacopan-treated patients, reflecting the survival of previously cleared cells rather than clonal expansion per se.

3. Pharmacodynamic breakthrough mitigation

Even with adequate C5 inhibitor plasma levels, strong complement triggers — infections, surgery, systemic inflammation — can generate high-density C3b deposition that correlates with residual terminal pathway activity and pharmacodynamic breakthrough hemolysis. Breakthrough hemolysis rates of 6.8–21.5 events per 100 patient-years have been reported with C5 inhibitors. Proximal inhibition prevents the C3b accumulation that seeds these breakthrough events, reducing rates to 0–3.2% of patients in iptacopan trials. This is particularly relevant for patients with high complement activation burden or intercurrent illness.

Safety profiles and infection risk across complement inhibitor classes

Both proximal and terminal complement inhibitors increase meningococcal infection risk by impairing complement-mediated killing of encapsulated bacteria, requiring vaccination against Neisseria meningitidis serogroups A, C, W, Y, and B prior to treatment initiation. This shared safety obligation reflects the systemic nature of complement inhibition across both drug classes.

Factor B/D inhibitors may theoretically pose a slightly higher infection risk due to more proximal pathway inhibition, which affects a broader segment of the complement cascade. However, long-term safety data spanning 4–5 years for iptacopan show comparable safety profiles to C5 inhibitors, with no unexpected increase in serious infections. Prophylactic antibiotics — such as penicillin — are recommended for high-risk patients on proximal inhibitors, consistent with guidance from the European Medicines Agency and national prescribing bodies.

The oral bioavailability of both iptacopan (twice daily) and danicopan (three times daily) represents a meaningful patient convenience advantage over the intravenous infusion schedules required for eculizumab (every two weeks) and ravulizumab (every eight weeks). For patients who travel frequently, live far from infusion centres, or have needle phobia, oral administration removes a significant treatment burden. This practical advantage is independent of the mechanistic superiority of proximal inhibition, and together they support the position of Factor B/D inhibitors as the preferred therapeutic approach for PNH patients with residual anemia or EVH — a view aligned with emerging clinical practice guidelines reviewed by the American Society of Hematology.

"For treatment-naïve PNH patients, iptacopan may be preferred as first-line therapy given its superior hematologic outcomes — achieving hemoglobin normalisation and transfusion independence rates that C5 inhibitors cannot match."

The clinical implication of this mechanistic and clinical evidence is a paradigm shift in PNH management: from the goal of controlling intravascular hemolysis to the more ambitious target of achieving complete hemolysis control and hemoglobin normalisation. For patients with residual anemia on C5 inhibitors, switching to iptacopan or adding danicopan should be strongly considered. For treatment-naïve patients, iptacopan monotherapy offers a comprehensive first-line option. The PatSnap innovation intelligence platform tracks the full complement inhibitor pipeline, including next-generation proximal pathway agents and combination strategies under investigation for PNH and related complement-mediated diseases. Access to PatSnap Eureka's drug intelligence tools enables R&D teams to map competitive positioning, freedom-to-operate, and emerging mechanistic targets across this rapidly evolving therapeutic area.